Trimeris (NASDAQ:TRMS)stock rocketed up $4.93 — nearly 10 percent–to close at $54.54, following a double-barreled blast of good news for the company and its anti-HIV drug Fuzeon Tuesday.

A Roche executive told a Reuter’s reporter at the International AIDS Society Conference on HIV Pathogenesis and Treatment in Paris that the company expects to have more of the Roche-Trimeris developed drug Fuzeon available this year than previously thought.

Trimeris presented Phase III clinical trial data on Fuzeon at the conference showing that experienced AIDS patients had sustained good responses to treatment with Fuzeon.

Prudential upgraded the stock to “buy” from “hold,” and increased its target price to $67 from $48.

Trimeris’ stock jumped nearly ten per cent Tuesday morning in response, moving from $53.80 to more than $55.32 in the course of the day. The volume of more than 2.5 million shares traded is about six times the daily average volume for Trimeris.

Fuzeon is the first of a new type of anti-HIV drugs called fusion inhibitors. In late-stage clinical trials, Fuzeon helped patients seriously ill with AIDS who were failing the traditional cocktail of anti-HIV drugs.

Trimeris has other fusion inhibitor drugs in clinical trials.